menu
    • menu
    [{"orgOrder":0,"company":"Antidote Therapeutics","sponsor":"National Institute on Drug Abuse | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"ATI-1013","moa":"Nicotine","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Antidote Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Antidote Therapeutics \/ National Institute on Drug Abuse | National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Antidote Therapeutics \/ National Institute on Drug Abuse | National Institutes of Health"}]

    Find Clinical Drug Pipeline Developments & Deals by Antidote Therapeutics

    Menu

    Antidote Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Antidote Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Antidote Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATI-1013

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : National Institute on Drug Abuse | National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers

                            Details : ATI-1013 is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Thromboangiitis Obliterans.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 14, 2025

                            Lead Product(s) : ATI-1013

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : National Institute on Drug Abuse | National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth